FCM regimen
WikiDoc Resources for FCM regimen |
Articles |
---|
Most recent articles on FCM regimen Most cited articles on FCM regimen |
Media |
Powerpoint slides on FCM regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on FCM regimen at Clinical Trials.gov Clinical Trials on FCM regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on FCM regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on FCM regimen Discussion groups on FCM regimen Patient Handouts on FCM regimen Directions to Hospitals Treating FCM regimen Risk calculators and risk factors for FCM regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for FCM regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:FCMR Regimen; R-FCM Regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone Regimen
Overview
FCM regimen refers to a regimen consisting of fludarabine, cyclophosphamide, mitoxantrone used to treat indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.[1]and along with rituximab for the treatment of CLL[2]
Regimen
FFludarabine
CCyclophosphamide
MMitoxantrone
Indications
- Indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.[3]
- CLL[2]
References
- ↑ "NCI Thesaurus".
- ↑ 2.0 2.1 Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.
- ↑ "NCI Thesaurus".